Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 2020. https://doi.org/10.1007/s11606-020-06124-2.

PMID
32875501
Full Text

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID
32392161
Full Text

Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer, August 5, 2020. https://doi.org/10.1002/cncr.33067.

PMID
32757302
Full Text

Rencsok, Emily M., Latifa A. Bazzi, Rana R. McKay, Franklin W. Huang, Adam Friedant, Jake Vinson, Samuel Peisch, et al. “Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.” Cancer Epidemiol Biomarkers Prev 29, no. 7 (July 2020): 1374–80. https://doi.org/10.1158/1055-9965.EPI-19-1616.

PMID
32503813
Full Text

Shore, Neal D., Fred Saad, Michael S. Cookson, Daniel J. George, Daniel R. Saltzstein, Ronald Tutrone, Hideyuki Akaza, et al. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” N Engl J Med 382, no. 23 (June 4, 2020): 2187–96. https://doi.org/10.1056/NEJMoa2004325.

PMID
32469183
Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID
32253061
Full Text

Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis, May 13, 2020. https://doi.org/10.1038/s41391-020-0236-0.

PMID
32404868
Full Text

Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, and Daniel J. George. “Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.” Adv Ther 37, no. 5 (May 2020): 2083–97. https://doi.org/10.1007/s12325-020-01260-x.

PMID
32112280
Full Text

Markham, Merry Jennifer, Kerri Wachter, Neeraj Agarwal, Monica M. Bertagnolli, Susan Marina Chang, William Dale, Catherine S. M. Diefenbach, et al. “Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” J Clin Oncol 38, no. 10 (April 1, 2020): 1081. https://doi.org/10.1200/JCO.19.03141.

PMID
32013670
Full Text

Pages